Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also i...
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 100
- Registration Number
- NCT02199665
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇺🇸Mayo Clinic (AZ), Scottsdale, Arizona, United States
🇺🇸Wayne State University Karmanos Cancer Institute, Detroit, Michigan, United States
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)
- Conditions
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 57
- Registration Number
- NCT02185820
- Locations
- 🇮🇹
Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Torino, Italy
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 10
- Registration Number
- NCT02187133
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸University of California, Davis, Davis, California, United States
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT02145403
- Locations
- 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
- Conditions
- Interventions
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT02142530
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02114502
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT02101944
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT02095834
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT02073097
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 63
- Registration Number
- NCT02056756
- Locations
- 🇮🇹
Divisione di Ematologia A.O.U. Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi di Ancona, Ancona, Italy
🇮🇹Fondazione EMN Italy Onlus, Torino, TO, Italy
🇩🇪Universitätsklinikum Schleswig-Holstein (UKSH) - Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Kiel, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.